摘要
目的观察非小细胞肺癌(non-small cell lung cancer, NSCLC)患者癌组织miR-129、干扰素调节因子-2(interferon regulatory factor-2, IRF-2)表达变化,探讨其与NSCLC患者临床病理特征及预后的关系。方法 NSCLC患者84例,均行胸腔镜下肺叶切除+淋巴结清扫术,术后采用吉西他滨联合顺铂方案化疗6个周期。采用实时荧光定量PCR法检测手术切除癌组织及癌旁组织miR-1290、IRF-2 mRNA相对表达量;比较不同临床病理特征NSCLC患者癌组织miR-1290、IRF-2 mRNA相对表达量;Pearson相关法分析NSCLC患者癌组织miR-1290与IRF-2表达的相关性。依据癌组织miR-1290、IRF-2 mRNA相对表达量中位数,将NSCLC患者分为miR-1290高表达组(miR-1290相对表达量≥3.06)43例和miR-1290低表达组(miR-1290相对表达量<3.06)41例,IRF-2高表达组(IRF-2 mRNA相对表达量≥0.72)40例和IRF-2低表达组(IRF-2 mRNA相对表达量<0.72)44例。随访3年,比较miR-1290和IRF-2高、低表达组NSCLC患者的生存情况。结果癌组织miR-1290相对表达量(3.05±0.96)高于癌旁组织(1.12±0.37)(P<0.05),IRF-2 mRNA相对表达量(0.73±0.24)低于癌旁组织(1.89±0.52)(P<0.05);有淋巴结转移(5.12±1.83)、临床分期Ⅲ~Ⅳ期(3.94±2.03)者癌组织miR-1290相对表达量分别高于无淋巴结转移、临床分期Ⅰ~Ⅱ期者(2.77±1.16、2.63±0.99)(P<0.05);有淋巴结转移(0.18±0.06)、临床分期Ⅲ~Ⅳ期(0.56±0.04)者癌组织IRF-2 mRNA相对表达量分别低于无淋巴结转移、临床分期Ⅰ~Ⅱ期者(0.80±0.23、0.81±0.34)(P<0.05);不同年龄、性别、肿瘤直径、病理类型、分化程度及有无吸烟史者癌组织miR-1290、IRF-2 mRNA相对表达量比较差异均无统计学意义(P>0.05)。NSCLC组织miR-1290表达与IRF-2 mRNA表达呈负相关(r=-0.742,P<0.001)。84例NSCLC患者3年总生存率为42.86%;miR-1290高表达组3年总生存率(27.91%)低于miR-1290低表达组(58.54%)(P<0.05),IRF-2低表达组3年总生存率(29.55%)低于IRF-2高表达组(57.50%)(P<0.05)�
Objective To observe the expressions of miR-1290 and interferon regulatory factor-2(IRF-2)in cancer tissues and their relationships with the clinicopathological characteristics and prognosis of patients with non-small cell lung cancer(NSCLC).Methods Eighty-four patients with NSCLC underwent thoracoscopic lobectomy+lymph node dissection,followed by 6 cycles of gemcitabine+cisplatin.The relative expressions of miR-1290 and IRF-2 mRNA in cancer tissues and adjacent tissues were detected by real-time fluorescence quantitative PCR,and were compared in patients with different clinicopathological characteristics.Pearson correlation analysis was used to assess the correlation between miR-1290 and IRF-2 in cancer tissues.According to the relative expressions of miR-1290 and IRF-2 mRNA in cancer tissues,84 NSCLC patients were divided into 43 patients with miR-1290≥3.06(highly-expressed miR-1290 group)and 41 patients with miR-1290<3.06(lowly-expressed miR-1290 group),and into 40 patients with IRF-2≥0.72(highly-expressed IRF-2 group)and 44 patients with IRF-2 mRNA<0.72(lowly-expressed IRF-2 group).The patients were followed up for 3 years,and the survival was compared between highly-and lowly-expressed miR-1290 groups and between highly-and lowly-expressed IRF-2 groups.Results The relative expression of miR-1290 was higher in cancer tissues(3.05±0.96)than that in adjacent tissues(1.12±0.37)(P<0.05),while the relative expression of IRF-2 mRNA was lower in cancer tissues(0.73±0.24)than that in adjacent tissues(1.89±0.52)(P<0.05).The relative expressions of miR-1290 were higher in patients with lymph node metastasis and clinical stageⅢ-Ⅳ(5.12±1.83,3.94±2.03)than those in patients without lymph node metastasis and with clinical stageⅠ-Ⅱ(2.77±1.16,2.63±0.99)(P<0.05).The relative expressions of IRF-2 mRNA were lower in patients with lymph node metastasis and clinical stageⅢ-Ⅳ(0.18±0.06,0.56±0.04)than those in patients without lymph node metastasis and with clinical stageⅠ-Ⅱ(0.80±0.23,0.81±0.34)(P<0.
作者
蔡宏剑
王庆华
宋金霞
李晓
赵晓
CAI Hong-jian;WANG Qing-hua;SONG Jin-xia;LI Xiao;ZHAO Xiao(Depurtment of Oncology,the Eighth People's Hospital of Qingdao,Qingdao,Shandong 266000.China;Department of Res piratory,Jiaozhou Central Hospital,Qingdao,Shandong 266300,China;Department of Laboratory,the Eighth People's Hospital of Qingdao.Qingdao.Shandong 266000.China;Department of Omcology,the 971 Navy Hospital of PLA,Qingdao,Shandong 266000,China)
出处
《中华实用诊断与治疗杂志》
2021年第7期714-717,共4页
Journal of Chinese Practical Diagnosis and Therapy
基金
山东省医药卫生项目(2017WS049)。
